Mr. Ken d'Entremont reports

MEDEXUS SCHEDULES THIRD FISCAL QUARTER 2025 CONFERENCE CALL

Medexus Pharmaceuticals Inc. plans to host a conference call at 8 a.m. Eastern Time on Thursday, Feb. 6, 2025, to discuss Medexus's results for its third fiscal quarter ended Dec. 31, 2024. Medexus expects to file its financial statements and MD&A (management's discussion and analysis) after markets close on Feb. 5, 2025.

To participate in the call, please dial the following numbers:

• 888-506-0062 (toll-free) for Canadian and United States callers;
• 1-973-528-0011 for international callers;
• Access code: 571655.

A live webcast of the call will be available on the investors section of Medexus's corporate website.

A replay of the call will be available approximately one hour following the end of the call through Thursday, Feb. 13, 2025. To access the replay, please dial the following numbers:

• 877-481-4010 for Canadian and U.S. callers;
• 1-919-882-2331 for international callers;
• Conference ID: 51991.

A replay of the webcast will be available on the investors section of Medexus's corporate website until Friday, Feb. 6, 2026.

About Medexus Pharmaceuticals Inc.

Medexus is a leading specialty pharmaceutical company with a strong North American commercial platform and a growing portfolio of innovative and rare disease treatment solutions. Medexus's current focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy and dermatology.

We seek Safe Harbor.